VeriChip Corporation (NASDAQ: CHIP), a provider of RFID systems for healthcare and patient-related needs, announced today that the Company and its VeriMed? Patient Identification System was featured in a recorded segment on CBS' The Early Show on Wednesday, September 5, at approximately 7:45 a.m. EDT. In the segment, Dr. Joseph Feldman, chairman of emergency/trauma at Hackensack University Medical Center discussed the benefits of the VeriMed Patient Identification System, which identifies high-risk patients and their medical records in an emergency situation. In addition, Molly Phillips of the MOLLY Foundation for Diabetes Research was interviewed.

The show airs on the CBS Network from 7 a.m. to 9 a.m. eastern time. For more information on The Early Show, visit: http://www.cbsnews.com/sections/earlyshow/main500202.shtml.

About VeriChip Corporation

VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. The Company recently began marketing its VeriMed Patient Identification System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.

VeriChip Corporation is majority-owned by Applied Digital Inc. (NASDAQ: ADSX), which also owns a majority position in Digital Angel Corporation (AMEX: DOC). For more information on VeriChip, please call 1-800-970-2447, or email info@verichipcorp.com. Additional information can be found online at www.verichipcorp.com.

Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

VeriChip Corporation, Delray Beach
Allison Tomek, 561-805-8008
atomek@adsx.com
or
CEOcast
Dan Schustack, 212-732-4300